Rappl Catherine, Barbier Pascale, Bourgarel-Rey Véronique, Grégoire Catherine, Gilli Robert, Carre Manon, Combes Sébastien, Finet Jean-Pierre, Peyrot Vincent
FRE-CNRS 2737, Universités Aix-Marseille 1 et 2, Cytosquelette et Intégration des Signaux du Micro-Environnement Tumoral, 27 boulevard Jean Moulin, 13385 Marseille Cedex 5, France.
Biochemistry. 2006 Aug 1;45(30):9210-8. doi: 10.1021/bi060476g.
The synthesis of different 4-arylcoumarin analogues of combretastatin A-4 led to the identification of two new compounds (1 and 2) with potent cytotoxic activity on a CEM leukemia cell line and a third one completely inactive (compound 3). It was suggested that the cytotoxicity of compounds 1 and 2 may be related to their interaction with microtubules and tubulin, since these compounds inhibit microtubule formation from purified tubulin in vitro [Bailly et al. (2003) J. Med. Chem. 46 (25), 5437-5444]. In the present study, tubulin was identified as the main target of these molecules. We studied structure-activity relationships of these compounds using biological experiments specific for tubulin binding. The modification of cell cycle progression induced by compounds 1 and 2 was characterized by an apoptotic induction on human breast cells (HBL100). In addition, these two molecules disturbed cell survival by depolymerizing the microtubule network, leading to a mitotic block. We then determined the thermodynamic parameters of their interaction with purified tubulin by fluorescence spectroscopy and isothermal microcalorimetry. These results, together with a superimposition of the molecule on colchicine in the X-ray-determined three-dimensional structure model of tubulin-colchicine complex, allowed us to identify the pharmacophore of the combretastatin A-4 analogues responsible for their biological activity.
不同的康普他汀A-4的4-芳基香豆素类似物的合成,使得两种新化合物(1和2)得以鉴定,它们对CEM白血病细胞系具有强大的细胞毒性活性,而第三种则完全无活性(化合物3)。有人认为,化合物1和2的细胞毒性可能与其与微管和微管蛋白的相互作用有关,因为这些化合物在体外抑制从纯化的微管蛋白形成微管[贝利等人(2003年)《药物化学杂志》46(25),5437 - 5444]。在本研究中,微管蛋白被确定为这些分子的主要靶点。我们使用针对微管蛋白结合的生物学实验研究了这些化合物的构效关系。化合物1和2诱导的细胞周期进程的改变,其特征在于对人乳腺细胞(HBL100)的凋亡诱导。此外,这两种分子通过使微管网络解聚来干扰细胞存活,导致有丝分裂阻滞。然后,我们通过荧光光谱法和等温微量热法确定了它们与纯化的微管蛋白相互作用的热力学参数。这些结果,连同在微管蛋白 - 秋水仙碱复合物的X射线确定的三维结构模型中将分子与秋水仙碱叠加,使我们能够鉴定负责其生物活性的康普他汀A-4类似物的药效团。